Recursion Pharmaceuticals Inc Class A RXRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RXRX is a good fit for your portfolio.
News
-
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
-
Recursion to Participate in Upcoming Investor Conference
-
Recursion Publishes Annual Environmental, Social and Governance Report
-
Thinking about buying stock in BigBear.ai, MicroCloud Hologram, TRACON Pharmaceuticals, Spruce Biosciences, or Recursion Pharmaceuticals?
-
Thinking about buying stock in Recursion Pharmaceuticals, SoundHound AI, Cardiff Oncology, Mind Medicine, or Auddia?
-
Recursion Announces Plans to Open New Office in London
-
Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community
-
Recursion to Participate in Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $7.60
- Day Range
- $7.55–7.92
- 52-Week Range
- $4.54–16.75
- Bid/Ask
- $8.20 / $8.28
- Market Cap
- $1.81 Bil
- Volume/Avg
- 15,796 / 6.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 36.48
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 500
- Website
- https://www.recursion.com
Comparables
Valuation
|
Metric
|
RXRX
|
CRNX
|
PMVP
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.88 | 5.44 | 0.39 |
Price/Sales | 36.48 | 622.39 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
RXRX
CRNX
PMVP
Financial Strength
|
Metric
|
RXRX
|
CRNX
|
PMVP
|
|---|---|---|---|
Quick Ratio | 4.24 | 12.92 | 14.47 |
Current Ratio | 4.70 | 13.07 | 14.78 |
Interest Coverage | −3,620.07 | — | — |
Quick Ratio
RXRX
CRNX
PMVP
Profitability
|
Metric
|
RXRX
|
CRNX
|
PMVP
|
|---|---|---|---|
Return on Assets (Normalized) | −41.77% | −38.81% | −23.12% |
Return on Equity (Normalized) | −59.93% | −44.79% | −25.57% |
Return on Invested Capital (Normalized) | −57.52% | −45.62% | −27.79% |
Return on Assets
RXRX
CRNX
PMVP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yctjmkdzs | Ltbp | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xyjrcybv | Djkjg | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zvlvycg | Wqslfx | $99.6 Bil | |
MRNA
| Moderna Inc | Vsplljk | Xtv | $38.8 Bil | |
ARGX
| argenx SE ADR | Fbzbhgdv | Wtvlk | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Cxjxxpf | Dtyw | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zgcnlwyw | Jrvtcdm | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Yrfvvsfv | Ppjgw | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dpxrdmqmm | Xlxngln | $12.4 Bil | |
INCY
| Incyte Corp | Tfklnvgd | Lvvgh | $11.9 Bil |